Please: Login/Register

The Latest Edition of "Eyes on malaria" magazine will be out very soon!! | CALL FOR ARTICLES: AMMREN is inviting journalists / writers / scientists interested in reporting on malaria to send articles for publication in its international magazine “Eyes on Malaria” and for posting on its website. Please contact the AMMREN Secretariat for more details click here. Enjoy your stay!. Volunteers and interns urgently needed to work with an NGO working in the area of malaria and health. Apply through - / Journalists interested in reporting on and writing articles on health issues should please reply through this email:




    Mosquitoes around the home can be reduced significantly by minimizing the amount of standing water available for mosquito breeding. Residents are urged to reduce standing water around the home in a variety of ways.


    The best way is to avoid being bitten by mosquitoes.This can be accomplished using personal protecting  while outdoors when mosquitoes are present. Treated bed nets should be used sleeping. Mosquito repellent should be used when outdoor.


    Nearly half of the world’s population is at risk of getting malaria. Pregnant women are particularly at risk of malaria. Children under 5 years are at high risk of malaria.


  • First Edition

  • Second Edition

  • Third Edition

  • Fourth Edition

  • Fifth Edition

  • Sixth Edition

  • Seventh Edition

  • Eighth Edition

  • Ninth Edition

  • Special Edition

  • INESS Edition

  • Tenth Edition

  • INDEPTH Edition

  • Eleventh Edition

  • Twelfth Edition

  • Special Edition

  • Special Edition

  • Volume 1

  • Volume 2

AMMREN welcomes announcement of pilot implementation on malaria vaccine,Mosquirix™

The African Media and Malaria Research Network (AMMREN) welcomes the announcement by the World Health Organization Regional Office for Africa (WHO/AFRO)on 24 April 2017, that Ghana, Kenya, and Malawi will take part in a WHO-coordinated pilot implementation programme that will make the world’s first malaria vaccine available in selected areas, beginning in 2018. 
In a statement issued in Accra by the Executive Secretary of AMMREN, Dr Charity Binka, to commemorate the 2017 World Malaria Day, she quoted the WHO and said, the injectable vaccine RTS,S was developed to protect young children from the most deadly form of malaria caused by Plasmodium falciparum and it will be assessed in the pilot programme as a complementary malaria control tool that could potentially be added to the core package of WHO-recommended measures for malaria prevention.
The statement said, in 2006, when AMMREN was established it worked closely with the Malaria Clinical Trials Alliance (MCTA) to roll out an advocacy programme on clinical trials.  The MCTA was a project of the INDEPTH Network set up to champion clinical trials and capacity development in Africa with the support from the Bill and Melinda Gates Foundation, which enabled the conduct of the largest phase 3 malaria vaccine trial on the RTS, S experimental drug. 
AMMREN sustained its advocacy project in malaria and on the RTS,S through the production of its flagship magazine, Eyes on Malaria, newspaper publications, radio programmes and documentaries devoted to giving visibility to various projects including the Malarial Clinical Trials Alliance and the vaccine, the statement added.
It explained that since 2007, AMMREN members, through its 10-member countries, followed the vaccine trials in Africa, visiting the 11 trial sites and reporting extensively on the project to sustain public interest in the final outcome of the malaria vaccine research that could lead to the acceptance of the vaccine when finally licensed. Five editions of our magazine specifically focused on the RTS,S vaccine. Editions of the magazine can be accessed at
According to the statement,  in line with its mission to sustain advocacy on malaria through a mix of old and new tool, AMMREN realized the need to actively engage various stakeholders in a Post - 2015 renewed agenda towards the elimination of malaria and the acceptance of the experimental RTS,S malaria vaccine.
The Network therefore convened a stakeholders’ meeting in June, 2015 at the Bellagio Conference Centre in Italy to develop and implement a strategic media framework for Africa under a Media Advocacy Project (MAP) to consolidate the gains made so far in the fight against malaria whilst positioning African communities to accept the RTS,S vaccine. 
AMMREN therefore sees the introduction of the vaccine in the three countries as an opportunity to step up advocacy directed to whipping up public support for the malaria elimination agenda and specifically for the vaccine. The Network is also calling on for the following actions:   
The training and equipping of journalists to promote accurate and effective dissemination of information on the vaccine and other tools to ensure that media content on the vaccine is well packaged and disseminated in a timely and accurate manner, nationally and globally
Building the capacity of scientists and researchers to communicate effectively with journalists from data generated from malaria research, tools and the vaccine
Facilitating widespread awareness of the RTS,S vaccine, particularly among family and community members to foster accurate understanding of the potential risks and benefits of the RTS,S malaria vaccine and the need for continued use of other malaria control measures.
The statement said: “AMMREN has over the years, laid a solid foundation for African journalists to partner with scientists and stakeholders in the fight to kick out malaria from the continent. Over the years, the skills of its journalists across Africa have also been sharpened to tell the malaria story as well as the RTS,S malaria vaccine story.”
The Network is therefore using this opportune time to call on all stakeholders to join it to carry out a sustained media advocacy project on the malaria elimination and to push for public acceptance of the RTS,S vaccine, ”it added.